Neurocrine Biosciences, Inc.

Healthcare · Biotechnology

Overall research band Above average

Quality Strong

Valuation Mixed

Balance sheet Exceptional

Market confirmation Mixed

One-minute company read

What this report can tell you now

What the company does

Neurocrine Biosciences, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing medicines for neurological, endocrine, and psychiatric disorders. Its main products include INGREZZA, a VMAT2 inhibitor for tardive dyskinesia; ONGENTYS, an adjunct therapy for Parkinson's disease; ORILISSA, for moderate to severe endometriosis pain; and ORIAHNN, an oral treatment for heavy menstrual bleeding due to uterine fibroids. The company also has a pipeline of experimental drugs targeting epilepsy, major depressive disorder, anhedonia, and schizophrenia. Neurocrine generates revenue primarily through the sale of its approved therapies and maintains strategic partnerships and licensing agreements with several pharmaceutical companies.

The current research profile is Market-Leading Quality, with strong market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Business quality is the strongest visible dimension. Check valuation before treating that strength as an investment conclusion.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC14.6%Model input; read with the evidence status and period context.

Operating margin21.6%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years26.0%Model input; read with the evidence status and period context.

FCF margin26.2%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.